News
BCTX
2.995
-1.16%
-0.035
BriaCell enters MoU with Uneedle for microneedle technology
TipRanks · 14h ago
BriaCell Therapeutics Inks MoU With Uneedle For Continued Use, Commercial Readiness Of Microneedle Technology For Intradermal Administration Of BriaCell’s Bria-IMT
Benzinga · 14h ago
BRIACELL THERAPEUTICS CORP - ENTERS MOU WITH UNEEDLE FOR MICRONEEDLE ADMINISTRATION OF BRIA-IMT
Reuters · 14h ago
BriaCell signs MoU with Uneedle on microneedle delivery for Bria-IMT breast cancer therapy
PUBT · 14h ago
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
Barchart · 19h ago
Weekly Report: what happened at BCTX last week (0615-0619)?
Weekly Report · 3d ago
BriaCell publishes investor presentation on Bria-IMT pivotal Phase 3 metastatic breast cancer program
PUBT · 6d ago
Weekly Report: what happened at BCTX last week (0608-0612)?
Weekly Report · 06/15 09:07
BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY
Benzinga · 06/09 22:08
BriaCell FY26 Q3 net loss widens to $7.24 million
PUBT · 06/09 20:07
BriaCell publishes investor presentation on Bria-IMT Phase 3 metastatic breast cancer program
PUBT · 06/09 18:47
Weekly Report: what happened at BCTX last week (0601-0605)?
Weekly Report · 06/08 09:07
BriaCell Therapeutics Completes Equity Offering to Fund Operations
TipRanks · 06/03 10:48
BriaCell prices best-efforts offering of 1,449,300 shares at $3.25 each, raising $4.7 million
PUBT · 06/03 10:04
BriaCell Therapeutics prices 1,449,300-share follow-on offering at $3.25 per share
PUBT · 06/02 20:09
BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF OFFERING
Reuters · 06/02 20:05
BriaCell Therapeutics Announces Closing of Offering
Barchart · 06/02 15:05
BriaCell reports 16.6-month median survival in Phase 2 Bria-IMT regimen for metastatic breast cancer patients at ASCO 2026
PUBT · 06/01 11:34
Weekly Report: what happened at BCTX last week (0525-0529)?
Weekly Report · 06/01 09:07
Reported Earlier, Cancer Drug Developer BriaCell Prices $4.7M Stock Offering Of 1.45M Shares At $3.25/Share to Fund Operations and Research
Benzinga · 06/01 07:51
More
Webull provides a variety of real-time BCTX stock news. You can receive the latest news about Briacell Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.